-
Tytuł:
-
Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.
-
Autorzy:
-
Slovak ML; Cytogenetics Laboratory, City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA. />O'Donnell M
Smith DD
Gaal K
-
Źródło:
-
Cancer genetics and cytogenetics [Cancer Genet Cytogenet] 2009 Sep; Vol. 193 (2), pp. 78-85.
-
Typ publikacji:
-
Comparative Study; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [New York] Elsevier/North-Holland.
-
MeSH Terms:
-
Chromosome Deletion*
Chromosomes, Human, Pair 1*
Chromosomes, Human, Pair 7*
Genetic Predisposition to Disease*
Myelodysplastic Syndromes/*genetics
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies
-
Entry Date(s):
-
Date Created: 20090812 Date Completed: 20090901 Latest Revision: 20090811
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.cancergencyto.2009.04.013
-
PMID:
-
19665067
-
The der(1;7)(q10;p10) aberration is observed in about 1-3% of the myelodysplastic syndromes (MDS) and less commonly in acute myeloid leukemia (AML) and the myeloproliferative disorders. This unbalanced translocation is considered a "variant" of the del(7q)/-7 subgroup and has been assigned a poor risk karyotype score in the MDS International Prognostic Scoring System (IPSS). Recent reports suggest der(1;7) MDS should be considered a discrete MDS subgroup with an intermediate, not poor, karyotype score. At the City of Hope, we compared the clinical-pathologic features of 12 der(1;7) MDS patients to 51 MDS patients with del(7q) (n=10) or -7 (n=41), selected for a similar frequency of secondary aberrations. The der(1;7) patients showed older age at diagnosis, lower platelet counts, less trilineage dysplasia, and lower blast counts. The der(1;7) patients did not differ from del(7q)/-7 patients in subtypes of MDS by World Health Organization, French-American-British classifications, or bone marrow cellularity. Neither the proportion of therapy-related MDS nor the transformation to AML differed significantly among the three subgroups. Five-year survival rates for der(1;7), del(7q), and -7 (44.4, 32.0, and 23.6%, respectively) did not differ significantly (P=0.94). While der(1;7) MDS is associated with some clinically distinctive features, reassignment of risk category based on these data would be premature.